Instil Bio Inc TIL

Healthcare Biotechnology

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.

NDAQ:TIL - Post by User

Instil Bio Inc

Bullboard Posts

Comment by migrantson May 01, 2014 12:02am

158 Views

Post# 22510829

RE:Assets

So if they have roughly $35 million in marketable assets, and roughly 3.5 million shares outstanding, NAV is roughly $10/share. This does not include the "Resource Re" thing; does it really have any value? I have no idea at all. There is no concrete information available that I see concerning any assets or cash flows.

Other companies with a similar business model (resource stock holding companies) are generally trading at around 50% of NAV. This does not look good...

Bullboard Posts

How a junior advances one of the largest undeveloped diamond projects